ADAR1 Capital Management LLC purchased a new stake in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 130,037 shares of the company's stock, valued at approximately $2,861,000. ADAR1 Capital Management LLC owned about 2.13% of Monopar Therapeutics at the end of the most recent quarter.
Separately, JPMorgan Chase & Co. purchased a new stake in Monopar Therapeutics in the 4th quarter valued at about $45,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several brokerages have weighed in on MNPR. Piper Sandler reaffirmed an "overweight" rating and set a $76.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. Jones Trading reaffirmed a "hold" rating on shares of Monopar Therapeutics in a research report on Wednesday, April 2nd. Finally, HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Monopar Therapeutics in a research report on Tuesday, April 1st.
Read Our Latest Report on Monopar Therapeutics
Insider Transactions at Monopar Therapeutics
In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the company's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the transaction, the insider now directly owns 822,255 shares of the company's stock, valued at approximately $28,778,925. This represents a 3.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 34.90% of the company's stock.
Monopar Therapeutics Stock Up 9.5 %
NASDAQ:MNPR traded up $3.02 on Friday, reaching $34.89. 14,762 shares of the company's stock were exchanged, compared to its average volume of 357,654. The business has a fifty day moving average of $36.82 and a 200-day moving average of $26.19. Monopar Therapeutics Inc. has a 52-week low of $1.72 and a 52-week high of $54.30. The firm has a market capitalization of $213.28 million, a price-to-earnings ratio of -17.71 and a beta of 1.01.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its earnings results on Monday, March 31st. The company reported ($2.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($1.87). As a group, equities analysts anticipate that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current year.
Monopar Therapeutics Company Profile
(
Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Read More
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
